Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to -$6.5 million.

  • Enanta Pharmaceuticals' Cash from Operations rose 3760.58% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.3 million, marking a year-over-year increase of 7553.2%. This contributed to the annual value of -$19.3 million for FY2025, which is 7553.2% up from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Cash from Operations of -$6.5 million as of Q3 2025, which was up 3760.58% from $17.5 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Cash from Operations high stood at $17.5 million for Q2 2025, and its period low was -$35.6 million during Q4 2022.
  • Over the past 5 years, Enanta Pharmaceuticals' median Cash from Operations value was -$16.8 million (recorded in 2024), while the average stood at -$18.0 million.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Cash from Operations plummeted by 55744.21% in 2021 and then soared by 21848.39% in 2025.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Cash from Operations stood at -$13.3 million in 2021, then plummeted by 168.56% to -$35.6 million in 2022, then grew by 29.89% to -$25.0 million in 2023, then surged by 32.76% to -$16.8 million in 2024, then surged by 61.38% to -$6.5 million in 2025.
  • Its last three reported values are -$6.5 million in Q3 2025, $17.5 million for Q2 2025, and -$13.5 million during Q1 2025.